AMRI, a contract research, development, and manufacturing organization, has appointed Paul Feuerman as senior vice president, general counsel, and head of business development.

Feuerman will be responsible for leading all AMRI’s legal, mergers and acquisitions, and corporate affairs activities for all the company’s locations. Lori M. Henderson, currently AMRI’s senior vice president, general counsel, and secretary, will transition in the coming months to pursue new opportunities.

Previously, Feuerman was assistant general counsel, global business development at Mylan, where he provided counsel in support of several business translations, including the $1.6-billion acquisition of the oncolytics and global injectables businesses of Agila, a generic-drug manufacturer; the $5.3-billion acquisition of Abbott’s non-US developed markets specialty and branded generics business; and divestitures in support of the $7.2-billion acquisition of Meda, a specialty pharmaceutical company. Prior to this, he served as general counsel for SciDose, a specialty pharmaceutical company. Earlier in his career, he served as general counsel at Axonyx, a biopharmaceutical company, and executive vice president and general counsel at Schein Pharmaceutical, a generic pharmaceutical company.

Source: AMRI